S&P 500   4,238.11 (-1.17%)
DOW   33,088.66 (-1.03%)
QQQ   356.05 (-1.44%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,238.11 (-1.17%)
DOW   33,088.66 (-1.03%)
QQQ   356.05 (-1.44%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,238.11 (-1.17%)
DOW   33,088.66 (-1.03%)
QQQ   356.05 (-1.44%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,238.11 (-1.17%)
DOW   33,088.66 (-1.03%)
QQQ   356.05 (-1.44%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
Top-Rated StocksTop-Rated
NASDAQ:AXNX

Axonics (AXNX) Stock Forecast, Price & News

$55.21
-2.10 (-3.66%)
(As of 12:32 PM ET)
Compare
Today's Range
$55.00
▼
$57.23
50-Day Range
$53.00
▼
$62.51
52-Week Range
$47.59
▼
$77.20
Volume
178,651 shs
Average Volume
650,930 shs
Market Capitalization
$2.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.36
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Axonics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
38.4% Upside
$76.36 Price Target
Short Interest
Bearish
6.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
1.11mentions of Axonics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.01 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to $0.07 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

250th out of 976 stocks

Surgical & Medical Instruments Industry

35th out of 100 stocks

See Top Rated MarketRank™ Stocks Here

AXNX stock logo

About Axonics (NASDAQ:AXNX) Stock

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Price History

AXNX Stock News Headlines

October 2, 2023 | finance.yahoo.com
Axonics to Report Third Quarter 2023 Financial Results on October 30
September 22, 2023 | finance.yahoo.com
Unveiling Axonics (AXNX)'s Value: Is It Really Priced Right? A Comprehensive Guide
October 3, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
September 11, 2023 | finance.yahoo.com
Axonics (AXNX): A Significantly Undervalued Gem in the Medical Technology Sector?
September 7, 2023 | seekingalpha.com
Axonics: Growing Duopolist With Superior Product And No Debt
August 25, 2023 | finance.yahoo.com
Axonics to Participate in September Investor Conferences
August 21, 2023 | finance.yahoo.com
Axonics Announces CFO Retirement and Appoints Successor
July 31, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Axonics Modulation Technologies (AXNX) and SAGE Therapeutics (SAGE)
October 3, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
July 29, 2023 | seekingalpha.com
Axonics: Rapid Growth But Waiting For Profitability
July 28, 2023 | markets.businessinsider.com
Analyst Ratings for Axonics
July 28, 2023 | finance.yahoo.com
Why Shares of Axonics Rose Friday
July 28, 2023 | washingtonpost.com
Axonics: Q2 Earnings Snapshot
July 24, 2023 | markets.businessinsider.com
Truist Financial Keeps Their Buy Rating on Axonics Modulation Technologies (AXNX)
July 18, 2023 | markets.businessinsider.com
Mizuho Securities Sticks to Its Buy Rating for Axonics Modulation Technologies (AXNX)
July 16, 2023 | markets.businessinsider.com
Truist Financial Remains a Buy on Axonics Modulation Technologies (AXNX)
July 13, 2023 | markets.businessinsider.com
Axonics Positioned For Rapid Penetration In Underserved Market, Analyst Initiates With Bullish Tone
July 13, 2023 | markets.businessinsider.com
KeyBanc Initiates a Buy Rating on Axonics Modulation Technologies (AXNX)
July 12, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Axonics
July 10, 2023 | reuters.com
US appeals court revives Axonics challenges to Medtronic device patents
June 29, 2023 | finance.yahoo.com
Axonics to Report Second Quarter 2023 Financial Results on July 27
May 31, 2023 | markets.businessinsider.com
Jefferies Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
May 31, 2023 | finance.yahoo.com
Even though Axonics (NASDAQ:AXNX) has lost US$173m market cap in last 7 days, shareholders are still up 28% over 3 years
May 23, 2023 | markets.businessinsider.com
Where Axonics Stands With Analysts
May 16, 2023 | finance.yahoo.com
What Makes Axonics (AXNX) Unique?
May 12, 2023 | seekingalpha.com
Axonics: Attractive Strong Growth Profile
May 8, 2023 | finance.yahoo.com
A Look At The Intrinsic Value Of Axonics, Inc. (NASDAQ:AXNX)
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Company Calendar

Last Earnings
7/27/2023
Today
10/03/2023
Next Earnings (Estimated)
10/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
CUSIP
N/A
CIK
1603756
Web
www.axonics.com
Phone
(949) 396-6322
Fax
949-396-6321
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$76.36
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+33.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,700,000.00
Net Margins
-10.06%
Pretax Margin
-10.73%
Return on Equity
-5.60%
Return on Assets
-4.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.19
Quick Ratio
12.01

Sales & Book Value

Annual Sales
$273.70 million
Price / Sales
10.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.51 per share
Price / Book
4.98

Miscellaneous

Outstanding Shares
50,460,000
Free Float
49,527,000
Market Cap
$2.89 billion
Optionable
Not Optionable
Beta
0.44
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Raymond W. CohenMr. Raymond W. Cohen (Age 64)
    CEO & Director
    Comp: $1.71M
  • Mr. Danny L. DearenMr. Danny L. Dearen (Age 60)
    Pres & CFO
    Comp: $799.08k
  • Mr. Rinda K. SamaMr. Rinda K. Sama (Age 44)
    Chief Operating Officer
    Comp: $902.83k
  • Dr. John Woock Ph.D. (Age 40)
    Exec. VP, Chief Marketing & Strategy Officer
    Comp: $902.83k
  • Mr. Alfred J. Ford Jr.Mr. Alfred J. Ford Jr. (Age 52)
    Chief Commercial Officer
    Comp: $902.96k
  • Ms. Kari Keese
    VP of Fin. & Accounting
  • Mr. Guangqiang Jiang Ph.D. (Age 49)
    Chief Technology Officer
  • Mr. Neil Bhalodkar
    VP of Investor Relations
  • Mr. Aaron Pettit
    Gen. Counsel & Chief Compliance Officer
  • Mr. Michael V. Williamson Esq. (Age 51)
    J.D., Sr. VP, Gen. & IP Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXNX Stock - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXNX shares.
View AXNX analyst ratings or view top-rated stocks.

What is Axonics' stock price forecast for 2023?

11 equities research analysts have issued 1-year target prices for Axonics' stock. Their AXNX share price forecasts range from $70.00 to $90.00. On average, they expect the company's share price to reach $76.36 in the next year. This suggests a possible upside of 33.2% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2023?

Axonics' stock was trading at $62.53 at the start of the year. Since then, AXNX stock has decreased by 8.3% and is now trading at $57.31.
View the best growth stocks for 2023 here.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our AXNX earnings forecast.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its quarterly earnings results on Thursday, July, 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The business had revenue of $92.90 million for the quarter, compared to the consensus estimate of $86.45 million. Axonics had a negative net margin of 10.06% and a negative trailing twelve-month return on equity of 5.60%. The firm's revenue was up 34.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.47) EPS.

What ETFs hold Axonics' stock?

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares U.S. Medical Devices ETF (IHI).

What guidance has Axonics issued on next quarter's earnings?

Axonics updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $57.31.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $2.89 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Axonics have?

The company employs 610 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -